Loading
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Previous close
$1.32
+$0.07 · +5.60%
Pre-market
$1.3297
+$0.0097 · +0.73%
Oct 8, 8:59 AM ET
Regular session · ET · Market data may be delayed.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Day range
Current $1.32
52-week range
Current $1.32
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
44
Mixed
Risk
63
High Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Day range
Current $1.32
52-week range
Current $1.32
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.41M USD | — | — | — | — |
| Gross profit | −1.41M USD | — | — | — | — |
| Research and development | 61.98M USD | 118.09M USD | 102.55M USD | 62.71M USD | 28M USD |
| Selling, general, and administrative | 19.33M USD | 25.99M USD | 23.59M USD | 20.92M USD | 13.67M USD |
| Operating expenses | 79.9M USD | 144.07M USD | 126.14M USD | 83.63M USD | 41.67M USD |
| Interest income | 1.86M USD | 5.64M USD | 8.88M USD | 1.81M USD | 100K USD |
| Depreciation and amortization | 1.41M USD | 1.75M USD | 1.52M USD | 691K USD | 249K USD |
| Operating income | −81.31M USD | −144.07M USD | −126.14M USD | −83.63M USD | −41.67M USD |
| Net income | −61.8M USD | −138.43M USD | −117.26M USD | −81.83M USD | −41.57M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.20
1430.30% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.57M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF1.07M0.00%95.4B USD0.05%$233.49-1.56%
iShares Micro-Cap ETFIWC273.57K0.02%1.33B USD0.60%$183.36-1.09%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM110K0.09%116.75M USD0.73%$15.97-0.38%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
